Early indications of antidiabetic potential for adenosine A1 agonist from Glaxo Wellcome June 24, 1999
Calyx scientists identify CLX-0301, a novel antidiabetic and candidate for clinical testing June 24, 1999
New peptide compounds from Calyx are first in a potential new class of oral antidiabetics June 23, 1999